Comparative efficacy and safety of topical olopatadine formulations for allergic conjunctivitis: a systematic review and network meta-analysis
Frontiers in Pharmacology · 02.11.2026 · 17
DOI: 10.3389/fphar.2026.1914064 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.11.2026. Verfasst von Caiju Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Allergic conjunctivitis (AC) affects 15%–40% of the global population. Traditional network meta-analyses often group different formulations of olopatadine into a single node, obscuring concentration-dependent variations. This network meta-analysis evaluated the relative efficacy and safety of distinct olopatadine concentrations (0.1%, 0.2%, 0.77%) against other topical anti-allergic or anti-inflammatory agents.
Methods
Registered in PROSPERO (CRD420261375330), this study systematically searched major databases up to 1 May 2026, for randomized controlled trials (RCTs) on adults with AC. Interventions evaluated olopatadine formulations (0.1% BID, 0.2% QD, 0.77% QD) as independent nodes alongside 0.05% epinastine, 0.025% ketotifen, 0.25% alcaftadine, 1.5% bepotastine, 0.2% loteprednol etabonate, or placebo. Frequentist random-effects network meta-analyses were performed.
Results
Nineteen randomized controlled trials (RCTs) encompassing 2,745 patients (5,141 eyes) were analyzed. For ocular itching (18 RCTs), 0.77% olopatadine demonstrated superior efficacy among dual-acting agents (SUCRA = 80.7%), significantly outperforming epinastine and ketotifen. For conjunctival hyperemia (17 RCTs), 0.25% alcaftadine demonstrated the highest likelihood of efficacy (SUCRA = 66.5%), whereas among olopatadine formulations, only 0.2% significantly outperformed placebo (SUCRA = 47.4%). Subgroup analyses showed that 0.77% olopatadine and 0.25% alcaftadine were particularly effective against acute itching in conjunctival allergen challenge models. Safety assessments across 11 RCTs yielded wide confidence intervals due to data sparsity, precluding definitive tolerability rankings. Although trial data predominantly reported mild adverse events, external evidence highlights key long-term safety concerns, notably intraocular pressure elevation associated with extended topical corticosteroid therapy such as 0.2% loteprednol etabonate.
Conclusion
Topical dual-acting agents demonstrate outcome-specific efficacy variations in allergic conjunctivitis management. Olopatadine 0.77% excels in pruritus control, whereas alcaftadine 0.25% provides the highest likelihood of hyperemia resolution. Clinical management should adopt a personalized step-ladder approach: utilizing potent once-daily dual-acting agents (0.77% olopatadine or 0.25% alcaftadine) as first-line therapy for acute or seasonal exposure. Short-term topical corticosteroids (such as 0.2% loteprednol etabonate) should be strictly reserved for severe natural exposure non-responsive to dual-acting agents, with mandatory intraocular pressure monitoring, before transitioning back to dual-acting maintenance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
- The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Zitieren
APA
Li, C., Gao, Y., & Wei, L. (2026). Comparative efficacy and safety of topical olopatadine formulations for allergic conjunctivitis: a systematic review and network meta-analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1914064
Vancouver
Li C, Gao Y, Wei L. Comparative efficacy and safety of topical olopatadine formulations for allergic conjunctivitis: a systematic review and network meta-analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1914064
BibTeX
@article{Li2026,
author = {Li, Caiju and Gao, Yuying and Wei, Lijuan},
title = {Comparative efficacy and safety of topical olopatadine formulations for allergic conjunctivitis: a systematic review and network meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1914064}
}
EUVIMED